Cephalosporins: A pharmacological update

Clinical Microbiology and Infection

Volumn 6, Issue S3, 2000, Pages 50-52

  Novelli, A ^a   Conti, S ^a   Cassetta, M I ^a   Fallani, S ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM; BETA LACTAMASE; BETA LACTAMASE C; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; PENICILLIN BINDING PROTEIN; PORIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; CONCENTRATION (PARAMETERS); CONTINUOUS INFUSION; DRUG EFFECT; DRUG EFFICACY; DRUG PENETRATION; DRUG PROTEIN BINDING; ENTEROBACTERIACEAE; GRAM NEGATIVE BACTERIUM; HYDROLYSIS; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; MEMBRANE CHANNEL; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR SIZE; NONHUMAN; PHYSICAL CHEMISTRY; PSEUDOMONAS; GRAM NEGATIVE INFECTION; GRAM POSITIVE BACTERIUM; HUMAN; MICROBIOLOGICAL EXAMINATION; PSEUDOMONAS AERUGINOSA; REVIEW;

CEPHALOSPORINS; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 17644434692     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2000.tb02041.x     Document Type: Article

References (16)

1. Hancock REW. Role of porins in outer membrane permeability. J Bacteriol 1987; 169: 929-33.
2. James PA, Reeves DS. Bacterial resistance to cephalosporins as a function of outer membrane permeability and access to their target. J Chemother 1996; 8: 37-47.
3. Nikaido H, Rosemberg EY, Foulds J. Porin channels in Escherichia coli: studies with betalactams in intact cells. J Bacteriol 1983; 153: 232-40.
4. Novelli A, Mazzei T, Cassetta MI, Fallani S, Conti S, Periti P. Outer membrane permeability of Gram-negative rods to cephalosporins. Abstract C106, 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA, 17-20 September 1995.
5. Zhanel GG, Hoban DJ, Harding GKM. The postantibiotic effect: a review of in vitro and in vivo data. DICP Ann Pharmacother 1991; 25: 153-63.
6. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995; 22: 89-96.
7. Craig WA, Gudmundsson S. Postantibiotic effect. In: Lorian V, ed. Antibiotics in Laboratory Medicine, third edn. Williams & Wilkins, 1991: 403-31.
8. Fremaux A, Sissia G, Geslin P. In vitro post antibiotic effect (PAE) of cefuroxime and three other beta-lactams against penicillin-susceptible and resistant Streptococcus pneumoniae [Abst. No. A112]. 34th ICAAC, Orlando, FL, 1994.
9. Hanberger H, Nilsson LE, Maller R, Nilsson M. Pharmacodynamics of beta-lactam antibiotics on Gram-negative bacteria: initial killing, morphology and postantibiotic effect. Scand J Infect Dis Suppl 1990; 74: 118-23.
10. Hanberger H, Nilsson LE, Nilsson M, Maller R. Post-antibiotic effect of beta-lactam antibiotics on gram-negative bacteria in relation to morphology, initial killing and MIC. Eur J Clin Microbiol Infect Dis 1991; 10: 927-34.
11. Kumar A, Hay MB, Maier GA, Dyke JW. Post-antibiotic effect of ceftazidime, ciprofloxacin, imipenem, piperacillin and tobramycin for Pseudomonas cepacia. J Antimicrob Chemother 1992; 30: 597-602.
12. Libby JM. Postantibiotic effect in Escherichia coli determined with real-time metabolic monitoring. Antimicrob Agents Chemother 1998; 42: 78-82.
13. Mackenzie FM, Milne KE, Gould IM. The effects of the morphological response of Enterobacteriaceae to cephalosporins on PAE and CERT. Scand J Infect Dis 1998; 30: 411-16.
14. Odenholt I, Lowdin E, Cars O. Studies of the killing kinetics of benzylpenicillin, cefuroxime, azithromycin, and sparfloxacin on bacteria in the postantibiotic phase. Antimicrob Agents Chemother 1997; 41: 2522-6.
15. Fitoussi F, Doit C, Sandin A et al. Killing activity of cefpirome against penicillin-resistant Streptococcus pneumoniae isolates from patients with meningitis in a pharmacodynamic model simulating the cerebrospinal fluid concentration profile. Antimicrob Agents Chemother 1995; 39: 2560-3.
16. Manduru M, Mihm LB, White RL, Friedrich LV, Flume PA, Bosso JA. In vitro pharmacodynamics of ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother 1997; 41: 2053-6.